Noribogaine is a G-Protein Biased κ-Opioid Receptor Agonist

Noribogaine is the principal human metabolite of ibogaine, an alkaloid historically used in west-central African traditional medicine and investigated for anti-addictive properties. Previous preclinical and some human data indicate that noribogaine reaches high concentrations in brain tissue after ibogaine administration, produces ibogaine-like reductions in self-administration of multiple drugs in animals, potentiates morphine analgesia and can prevent development of morphine tolerance. Despite these pharmacological effects, the molecular mechanisms at opioid receptors have remained unclear: earlier work reported neither conventional mu nor kappa agonism/antagonism in vivo, and prior in vitro findings suggested complex, non-classical interactions with opioid signalling pathways. To address this gap, Maillet and colleagues set out to characterise noribogaine's interactions with the mu (OPRM) and kappa (OPRK) opioid receptors using a combination of in vitro binding and functional assays and in silico docking and molecular dynamics. The study quantified binding affinities, measured G-protein activation using [35S]GTPgS stimulation and non-G-protein signalling using b-arrestin-2 recruitment assays, and compared noribogaine's pharmacology with ibogaine, 18-MC and several well characterised opioid ligands (for example nalmefene and 6'-GNTI). The aim was to determine whether noribogaine displays pathway-selective (biased) activity at these opioid receptors that could explain its atypical in vivo profile.

The experimental programme combined radioligand competition binding, functional G-protein activation assays, b-arrestin-2 recruitment assays and computational docking with molecular dynamics. Human OPRM- and OPRK-expressing CHO-K1 cell membranes and rat midbrain membranes were used for biochemical assays. Radioligand competition used [3H]U69,593 for OPRK and [3H]DAMGO for OPRM, with increasing concentrations of test compounds to derive IC50 and apparent Ki values (Cheng–Prusoff transformation). Non-specific binding was defined with 1 mM naloxone. Data fitting was performed in GraphPad Prism. G-protein pathway activity was assessed by [35S]GTPgS binding to Gα proteins in membrane preparations. Membranes were pre-incubated with GDP and exposed to test ligands; bound tracer was separated by filtration and counted. EC50 and EMax values were obtained by non-linear regression. Antagonist functional inhibition constants (Ke) were calculated from agonist EC50 shifts or concentration-inhibition curves using standard equations. For the non-G-protein pathway, b-arrestin-2 recruitment was measured using the PathHunter enzyme complementation assay in CHO-K1 cells co-expressing human opioid receptors and an enzyme fragment–tagged b-arrestin-2; agonist-treated cells were typically incubated 180 min prior to readout, and antagonist incubations used a 30 min pre-treatment. Quantitative descriptors were derived to compare binding and functional potencies: pKi-pEC50 (activation coupling efficiency or e-coupling) links apparent affinity and potency, e-signal (efficacy efficiency) compares maximal responses against reference full agonists, and bias-coupling quantified pathway preference by comparing G-protein versus b-arrestin readouts after correcting for intrinsic assay efficiencies. Computational work used the mouse mu opioid receptor co-crystal (PDB 4dkl) as a template (94% identity to human OPRM in the binding site). Ligands were prepared and docked into the orthosteric site using Schrodinger tools (Glide, Prime) and representative complexes were subjected to 12 ns molecular dynamics in an explicit membrane and solvent environment in Desmond. Trajectories were analysed for key interactions and representative frames extracted for visualisation.

Binding affinities showed that noribogaine bound more tightly to human OPRK than to OPRM: Ki for OPRK was 720 ± 128 nM, while for OPRM it was 1.52 ± 0.3 mM. By comparison, ibogaine and 18-MC had weaker apparent affinities at OPRK (ibogaine Ki ~3.68 ± 0.22 mM; 18-MC Ki ~1.84 ± 0.12 mM) and at OPRM. These values were broadly consistent with assays on calf receptors and with historical literature values presented by the authors. In the G-protein activation assay ([35S]GTPgS), noribogaine acted as a partial agonist at OPRK: it stimulated GTPγS binding with an EMax of 72 ± 3.8% of the full agonist U69,593 and an EC50 of 8.75 ± 1.09 mM. By contrast, ibogaine showed much lower efficacy (E Max 18 ± 1.4%) and 18-MC failed to stimulate G-protein activation. Full agonists dynorphin A and U69,593 produced EMax values of ~94% and ~91% respectively. Noribogaine’s agonist effect was also observed in rat midbrain membranes and was sensitive to the kappa antagonist nor-BNI, supporting activity at native OPRK. When tested as a competitor in G-protein assays, classical kappa antagonists (naloxone, nor-BNI) and partial agonist nalmefene produced rightward shifts in agonist concentration–response curves with functional Ke values close to their Kis, consistent with competitive behaviour. Noribogaine behaved atypically: at concentrations manyfold higher than its Ki it poorly shifted the EC50 of dynorphin A and morphine, yielding estimated Ke values (~40 ± 16 mM and ~15 ± 4 mM) roughly 40-fold higher than its Ki. Noribogaine reduced the maximal activation of more efficacious agonists to its own EMax (~70%) but only at high concentrations (IC50 in the 100–300 mM range), a profile the authors describe as atypical and possibly protean. In b-arrestin-2 recruitment assays at OPRK, noribogaine was markedly weak: EMax was 13 ± 3% with an estimated EC50 of 110 nM, whereas dynorphin A had an EC50 of 11 ± 2 nM. Quantitative coupling analyses indicated a strong activation bias in favour of G-protein signalling: noribogaine showed an activation coupling preference of approximately 1:630 (G-protein vs b-arrestin) under the experimental conditions, and its activation efficacy bias was greater than that of the known biased ligand 6'-GNTI. Noribogaine also acted as an inhibitor of agonist-induced b-arrestin recruitment: it reduced dynorphin A–induced b-arrestin signalling by up to ~60% with an IC50 of 1 ± 0.16 mM. In contrast, in parallel assays assessing inhibition of dynorphin-induced G-protein signalling, noribogaine produced only minimal inhibition (~5%) and had much weaker apparent potency (IC50 ~150 mM). Thus noribogaine functioned as a more potent inhibitor of the b-arrestin pathway than of G-protein activation at OPRK. At OPRM, noribogaine was a marginal G-protein agonist (EMax ~10% of DAMGO/[met]-enkephalin) with an approximate EC50 of 16 mM. Functional inhibition experiments showed noribogaine behaved as a weak antagonist at mu receptors, shifting EC50s of mu agonists and yielding Ke values around ~20 mM. Noribogaine inhibited mu b-arrestin recruitment with an IC50 of ~100 ± 25 mM and, overall, was characterised as an unbiased mu antagonist in terms of pathway preference although it was an outlier in inhibition coupling efficiency compared with classical mu antagonists. Computational docking and 12 ns molecular dynamics of noribogaine and ibogaine in an inactive OPRM crystal structure placed both ligands in the morphinan orthosteric pocket, forming a hydrogen bond via the tertiary amine to Asp147 and multiple hydrophobic and pi interactions with surrounding residues (for example Tyr148, His297). Noribogaine uniquely formed a transient water bridge with Tyr148 during part of the simulation. The in silico interaction patterns aligned with the experimental affinity ranking.

Maillet and colleagues interpret their findings as demonstrating that noribogaine is a G-protein biased kappa opioid receptor agonist and a weaker mu receptor antagonist. The authors note that the potencies and biased profile they observed are compatible with brain concentrations reported after therapeutic ibogaine dosing, supporting physiological relevance. Because noribogaine stimulated G-protein signalling at OPRK while poorly recruiting b-arrestin, the researchers suggest this pharmacology could underlie noribogaine’s capacity to produce certain analgesic effects without the dysphoria typically associated with kappa agonists; the paper also links central OPRK activation to previously reported prolactin release after noribogaine. The study group highlights that noribogaine’s ability to inhibit dynorphin-induced b-arrestin recruitment while preserving G-protein signalling could modulate overactive dynorphin/kappa pathways observed in stress, anxiety and substance dependence. They propose this functional inhibition bias as a mechanistic basis for potential anxiolytic or antidepressant-like effects and for noribogaine’s modulation of opioid tolerance and morphine analgesia, citing parallels with genetic deletion of b-arrestin-2 and with reports that low-dose kappa agonists can reduce morphine tolerance. Comparisons with ibogaine and 18-MC emphasise distinct pharmacologies: ibogaine is a stronger mu antagonist but weaker kappa agonist than noribogaine, whereas 18-MC behaved as a non-specific micromolar competitive antagonist in these assays. The authors caution that 18-MC and noribogaine should not be considered pharmacologically equivalent. Mechanistically, noribogaine does not appear to act as an allosteric ligand because it competes for orthosteric radioligand binding and its behaviour in functional assays is consistent with orthosteric interaction. Instead, the authors propose that noribogaine stabilises a unique set of receptor conformations—accessible states that favour G-protein coupling but disfavour b-arrestin recruitment—consistent with multistep activation models of GPCRs. Finally, they acknowledge that further work is needed: direct in vivo studies in wild-type and genetically modified animals, deeper molecular investigations into receptor conformational dynamics and discrete drug–receptor interaction studies would help clarify the mechanistic and therapeutic implications of noribogaine’s biased pharmacology.

The study concludes that noribogaine acts as a dual ligand at mu and kappa opioid receptors, exhibiting pronounced G-protein biased agonism at kappa receptors and weak antagonism at mu receptors. By modulating dynorphin signalling at OPRK in a pathway-selective manner, noribogaine’s cellular pharmacology provides a plausible mechanistic basis for some of its reported in vivo effects and suggests avenues for further therapeutic exploration.